Canada markets open in 6 hours 3 minutes
  • S&P/TSX

    21,188.19
    +101.20 (+0.48%)
     
  • S&P 500

    4,536.19
    +16.56 (+0.37%)
     
  • DOW

    35,609.34
    +152.03 (+0.43%)
     
  • CAD/USD

    0.8110
    -0.0011 (-0.13%)
     
  • CRUDE OIL

    84.25
    +0.38 (+0.45%)
     
  • BTC-CAD

    80,147.02
    +806.16 (+1.02%)
     
  • CMC Crypto 200

    1,531.62
    +50.81 (+3.43%)
     
  • GOLD FUTURES

    1,782.70
    -2.20 (-0.12%)
     
  • RUSSELL 2000

    2,289.77
    +13.85 (+0.61%)
     
  • 10-Yr Bond

    1.6360
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,330.25
    -47.25 (-0.31%)
     
  • VOLATILITY

    15.49
    -0.21 (-1.34%)
     
  • FTSE

    7,195.94
    -27.16 (-0.38%)
     
  • NIKKEI 225

    28,708.58
    -546.97 (-1.87%)
     
  • CAD/EUR

    0.6962
    -0.0003 (-0.04%)
     

Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held in a virtual setting on Wednesday, September 22, 2021 at 12:25pm ET.

A webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived on the Company’s website for 90 days following the presentation.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting